Younger adults hit hardest by pandemic-related anxiety and depression

A JAMA Network Open study reveals age-related disparities in anxiety and depression among U.S. adults during the COVID-19 pandemic, with younger adults (18-39 years) experiencing higher levels of these mental health issues.

Genespire raises $52m in Series B to trial paediatric gene therapy

Genespire’s GENE202 was developed using the company’s Immune Shielded Lentiviral Vector (ISLV) platform that allows a patient’s liver to produce the therapy throughout its lifetime.

September 25, 2024

Healthcare companies harness AI to navigate supply chain challenges

New research by Economist Impact and supported by DP World reveals that 46% of companies in the healthcare sector are using Artificial Intelligence (AI) to identify

January 22, 2024

New Pluvicto data point to a potential wider indication, but Novartis leaves regulatory timeline up in the air: #ESMO23

MADRID — Novartis’ radiopharmaceutical drug Pluvicto staved off prostate cancer progression for a median of six months longer than hormone therapy in a pivotal study,

October 24, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.